Hybrigenics develops new oral formulations of inecalcitol

Published: 3-Nov-2010
Ingredients Drug Delivery Pharmaceutical

New capsules are more concentrated in inecalcitol and contain a fixed 2mg amount that will be more convenient, with a maximum of two small capsules to swallow, which also favours compliance

French biopharmaceutical group Hybrigenics has filed a patent application covering new soft gelatin capsules, tablets or drinking solutions optimised for the delivery of high doses of inecalcitol.

This pharmaceutical optimisation follows the demonstration of safety and the presumption of efficacy of oral doses as high as 4mg of inecalcitol per day in a Phase IIa clinical tolerance study in hormone-refractory prostate cancer patients.

Microdosed vitamin D analogues are currently marketed as oily solutions in soft gelatin capsules. The first formulations of inecalcitol were also soft gel capsules of different increasing concentrations and strengths, up to a maximum of 1mg unit dose. Patients treated at the highest tolerated dose had to swallow four such capsules.

The new capsules are more concentrated in inecalcitol and contain a fixed 2mg amount. Hybrigenics says treatment will therefore be more convenient with a maximum of two small capsules to swallow, which also favours compliance.

Inecalcitol has also been formulated as 2mg scored tablets, which provides the flexibility to adjust doses 1mg by 1mg. Drinking solutions of inecalcitol in a liquid excipient could provide complete dose proportionality to body weight, for paediatric indications for example.

Hybrigenics says pharmaceutical stability and human bioavailability studies in healthy volunteers are ongoing. It aims to start Phase IIb efficacy clinical trials in hormone-refractory prostate cancer and severe psoriasis with a formulation suitable for future commercialisation.

‘We have worked hard to reduce the size of soft gel capsules and to make tablets feasible, against all odds,’ said Rémi Delansorne, chief executive of Hybrigenics.

‘The new formulations are smaller, cheaper, more convenient and flexible to use. Moreover, we believe they are novel and inventive for a vitamin D analogue such as inecalcitol, potentially paving the road for patent protection until 2030.’

See more

You may also like

Research & Development

Hybrigenics and Servier sign three-year research deal

Read more
Will study deubiquitinating enzymes (DUBs) applied to a number of therapeutic areas

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    From injection to ingestion: can yeast make vaccines more accessible? As global vaccination coverage declines and distribution challenges persist, researchers are exploring edible yeast-based vaccines as a simpler, more scalable alternative to injections
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    AI might find the molecule, but delivery decides whether it becomes a medicine As the pharmaceutical industry scales AI-driven discovery at unprecedented speed, will the early integration of formulation and manufacturability determine which computationally promising molecules become deliverable medicines?
  3. Optimising process steps and performance with agitated Nutsche filter-dryers Agitated Nutsche filter dryers (ANFD) streamline solid-liquid separation by performing filtration, dewatering, and drying in a single sealed vessel; an enormous boon in fine chemicals and pharmaceutical production
  4. IMA strengthens aseptic and containment capabilities with ProSys acquisition The deal expands IMA’s isolator and sampling technology portfolio for the global biopharmaceutical market

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Research & Development

Hybrigenics and Servier sign three-year research deal

Will study deubiquitinating enzymes (DUBs) applied to a number of therapeutic areas
Ingredients

Hybrigenics improves inecalcitol synthesis

French firm makes patent application for high-yield inecalcitol production
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

AI might find the molecule, but delivery decides whether it becomes a medicine

As the pharmaceutical industry scales AI-driven discovery at unprecedented speed, will the early integration of formulation and manufacturability determine which computationally promising molecules become deliverable medicines?
Ingredients

Sequential extraction kit enables multiomics analysis from a single sample

Thermo Fisher Scientific launches a magnetic bead-based workflow to support genomic, transcriptomic and proteomic research
Manufacturing

CARBOGEN AMCIS and Celonic unveil integrated ADC development platform at World ADC London 2026

The strategic alliance combines biologics and highly potent payload capabilities to streamline ADC development and manufacturing
Pharmaceutical

Optimising process steps and performance with agitated Nutsche filter-dryers

Agitated Nutsche filter dryers (ANFD) streamline solid-liquid separation by performing filtration, dewatering, and drying in a single sealed vessel; an enormous boon in fine chemicals and pharmaceutical production
Drug Delivery

Automating processes for effective scale-up with the GFD Lab PLUS Filter Dryer

Scale-up is a persistent challenge in fine chemical and pharmaceutical manufacturing. Countless challenges arise when translating workflows from the lab, or pilot-scale, to commercial production. But issues can occur even earlier. Inconsistencies during early development can lead directly to scale-up failures
Subscribe now